Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-25T19:38:06.210Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study

Published online by Cambridge University Press:  19 December 2005

Volker Mall ,
Florian Heinen ,
Andrea Siebel ,
Christoph Bertram ,
Ulrich Hafkemeyer ,
Jörg Wissel ,
Steffen Berweck ,
Fritz Haverkamp ,
Günter Nass  and
Leo Döderlein
...Show all authors
Volker Mall
Affiliation:
Children's University Hospital, Freiburg University, Freiburg, Germany.
Florian Heinen
Affiliation:
Department of Paediatric Neurology and Developmental Medicine, Ludwig-Maximilians-University München, München, Germany.
Andrea Siebel
Affiliation:
IPSEN-Pharma GmbH, Ettlingen, Germany.
Christoph Bertram
Affiliation:
Department of Orthopaedic Surgery, University of Cologne, Cologne, Germany.
Ulrich Hafkemeyer
Affiliation:
Department of Orthopaedic Surgery, Münster University, Münster, Germany.
Jörg Wissel
Affiliation:
Department of Neurology, University of Innsbruck, Innsbruck, Austria.
Steffen Berweck
Affiliation:
Department of Paediatric Neurology and Developmental Neuroscience, Ludwig-Maximilians-University München, München, Germany.
Fritz Haverkamp
Affiliation:
Children's University Hospital, Bonn University, Bonn, Germany.
Günter Nass
Affiliation:
Department of Child Neurology, Maulbronn, Germany.
Leo Döderlein
Affiliation:
Department of Orthopedic Surgery, University of Heidelberg, Heidelberg, Germany.
Nico Breitbach-Faller
Affiliation:
Children's Hospital, Esslingen, Germany.
Wilhelm Schulte-Mattler
Affiliation:
Department of Neurology, Regensburg University, Regensburg, Germany.
Rudolf Korinthenberg
Affiliation:
Children's University Hospital, Freiburg University, Freiburg, Germany.
Get access

Abstract

Adductor spasticity in children with cerebral palsy (CP) impairs motor function and development. In a placebo-controlled, double-blind, randomized multicentre study, we evaluated the effects of botulinum toxin A(BTX-A) in 61 children (37 males, 24 females; mean age 6 years 1 month [SD 3y 1mo]) with CP (leg-dominated tetraparesis, n=39; tetraparesis, n=22; GMFCS level I, n=3; II, n=6; III, n=17; IV, n=29; V, n=6). Four weeks after treatment, a significant superiority of BTX-A was observed in the primary outcome measure (knee–knee distance ‘fast catch’, p=0.002), the Ashworth scale (p=0.001), and the Goal Attainment Scale (p=0.037).

Type
Original Articles
Information
Developmental Medicine and Child Neurology , Volume 48 , Issue 1 , January 2006 , pp. 10 - 13
Copyright
© 2006 Mac Keith Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)